Drug intelligence / Profile preview

科荟生AVBER

Development stage: Preclinical
Lead developer: 广州市东源药业科技有限公司
Administration: Topical (microemulsion)

Overview

科荟生AVBER is a drug used for treating foot ulcers due to nerve damage. It is involved in a clinical study to evaluate its effectiveness and safety in promoting ulcer healing and nerve repair.

Other names: Kehuisheng + AVBER

Beyond the preview

Go deeper on 科荟生AVBER.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 科荟生AVBER.